ArticleClinical pharmacokinetics2015
Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
Article in Clinical pharmacokinetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Model-Informed Precision Dosing in Pediatric Patients: Current Software Tools and Bedside Guided Application.Paediatric drugs · 2026Pooled it
- A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.British journal of clinical pharmacology · 2020Pooled it
- Model-Informed Drug Development (MIDD) for Analgesics: Review of Applications, Regulatory Integration, and Emerging Directions.Journal of pain research · 2026Review
- Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.European journal of hospital pharmacy : science and practice · 2024Article
- Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?JAC-antimicrobial resistance · 2023Review
- Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clinical pharmacokinetics · 2021Review
- Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.Clinical pharmacokinetics · 2021Review
- Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring.Research in pharmaceutical sciences · 2020Review
- An Introduction to Machine Learning.Clinical pharmacology and therapeutics · 2020Review
- Optimising antimicrobial therapy through the use of Bayesian dosing programs.International journal of clinical pharmacy · 2019Review
- An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting.British journal of clinical pharmacology · 2019Article
- Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?Clinical pharmacokinetics · 2019Article
- What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.The AAPS journal · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
- Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2018Article
- Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update.Antimicrobial agents and chemotherapy · 2018Article
- Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Clinical and translational science · 2017Review
- Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Antimicrobial agents and chemotherapy · 2016Article
- Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSeveral dosage adjustment methods are currently available to individualize intravenous tobramycin dosing. This study compared different methods in terms of their recommendations for dosage adjustment, their estimation of patients' pharmacokinetic parameter values and their ability to predict subsequent observed tobramycin concentrations following once-daily tobramycin treatment in children and adolescents with cystic fibrosis.
methodsRetrospective data from 172 patients treated at the Royal Children's Hospital (Brisbane, QLD, Australia) were analysed. To be included in the analysis, each patient had to have at least one pair of tobramycin plasma concentration-time measurements recorded over a dosing interval. One or both of the concentrations in the paired set were applied in each of the following dosage adjustment methods: (i) the Therapeutic Guidelines Aminoglycoside nomogram; (ii) the Massie nomogram; (iii) log-linear regression analysis; and two Bayesian forecasting software programs: (iv) TCIWorks and (v) DoseMe. All methods were compared in regard to their recommendations for tobramycin dosage adjustment. The latter three methods were also examined in terms of estimated pharmacokinetic parameter values and their ability to predict subsequent observed tobramycin concentrations.
resultsThe Therapeutic Guidelines nomogram recommended significantly greater mean doses for dosage adjustment (27.0 mg/kg) compared with all other methods (p ≤ 0.01), which gave similar mean dose recommendations (11.6-14.6 mg/kg); however, >20 % differences in doses on an individual level were seen on 20-35 % of occasions across all methods. The log-linear regression analysis method and the two Bayesian forecasting methods (TCIWorks and DoseMe) showed negligible bias but imprecision of around 20 % in predicting subsequent observed tobramycin concentrations. The Bayesian forecasting methods showed no significant difference in mean dose recommendations when using either one or two concentration measurements but increased imprecision in predicting subsequent observed tobramycin concentrations.
conclusionThe log-linear regression method and Massie nomogram are likely to be suitable alternative methods for tobramycin dosage adjustment when Bayesian forecasting software is unavailable. The Therapeutic Guidelines nomogram should not be used to aid dose adjustment of tobramycin therapy in children with cystic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.